Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bluebird Bio 455 GRAND UNION BOULEVARD SOMERVILLE MA 02145 USA

www.bluebirdbio.com P: 339-499-9300

Description:

bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.'The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent '-thalassemia (TDT).

Key Statistics

Overview:

Market Capitalization, $K 99,769
Enterprise Value, $K -13,241
Shares Outstanding, K 109,336
Annual Sales, $ 3,600 K
Annual Net Income, $ -266,580 K
Last Quarter Sales, $ 12,390 K
Last Quarter Net Income, $ -71,730 K
EBIT, $ -238,160 K
EBITDA, $ -233,160 K
60-Month Beta 0.74
% of Insider Shareholders 2.10%
% of Institutional Shareholders 87.43%
Float, K 107,040
% Float 97.90%
Short Volume Ratio 0.53

Growth:

1-Year Return -75.27%
3-Year Return -96.96%
5-Year Return -99.36%
5-Year Revenue Growth -89.84%
5-Year Earnings Growth 57.20%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.66 on 11/07/23
Latest Earnings Date 05/14/24
Earnings Per Share ttm -0.74
EPS Growth vs. Prev Qtr 1.49%
EPS Growth vs. Prev Year 28.26%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

BLUE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -7,405.00%
Debt/Equity 0.00
Price/Sales 4.26
Price/Cash Flow N/A
Price/Book 0.47
Book Value/Share 2.08
Interest Coverage -5.69
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar